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IABSTRACT
The effect of DPP-4 inhibitor on angiogenic 
regeneration by bone marrow mesenchymal stem cell in 
hindlimb ischemia injury model
Heejung Lim
Graduate program of Science for Aging
The Graduate School, Yonsei University
(Directed by Professor Young-Guk Ko)
Background: Mesenchymal stem cells (MSCs) are known to have a therapeutic 
potential for severe limb ischemia. However, poor survival of implanted MSCs 
in the target tissue remains as an important factor that attenuates the angiogenic 
II
potential of the cell therapy.
Thus, we investigated whether sitagliptin, a DPP-4 inhibitor, may enhance the 
angiogenic efficacy of MSC in a hind limb ischemia murine model by 
increasing production of SDF-1. 
Methods and Results: Mice with induced hind limb ischemia were devided 
into 4 groups; group 1 treated with oral saline and local injection of saline, 
group 2 treated with oral sitagliptin and local injection of saline, group 3 treated 
with oral saline and local injection of MSCs, and group 4 treated with oral 
sitagliptin and local injection of MSCs. Angiogenic responses were measured 
by laser-Doppler perfusion imaging, muscle capillary density, and protein and 
mRNA expression of SDF-1, CXCR4, and vascular endothelial growth factor
VEGF growth factors and compared among the treatment groups.
The combined treatment of oral sitagliptin and local injection of MSCs 
achieved more effective angiogenic response than oral sitagliptin administration 
or local MSC transplantation alone in a mouse hind limb ischemia model. The 
combination therapy also demonstrated increased expression of VEGF, SDF-1 
and CXCR4 in hind limb ischemia models.
Conclusion: The combination therapy of oral sitagliptin and local 
III
transplantation of MSCs was more effective in enhancing angiogenic responses
to ischemia than oral sitagliptin or local transplantation of MSCs alone possibly 
due to up-regulation of SDF-1.
Key Words: Hind-limb ischemia, sitagliptin, SDF-1/CXCR4, angiogenesis, 
Laser Doppler
1The effect of DPP-4 inhibitor on angiogenic 
regeneration by bone marrow mesenchymal stem cell in 
hindlimb ischemia injury model
Heejung Lim
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I. INTRODUCTION
Critical limb ischemia (CLI), disease known to affect quality of life and 
survival, is the most severe form of occlusive atherosclerosis. It is a terminal 
2peripheral artery disease and presents with chronic ischemic pain, ulcers and/or 
tissue gangrene 1-4. These patients frequently have multiple levels of vascular 
obstruction making collateral blood vessel formation difficult. When 
endovascular or surgical treatment fails or is not feasible, there are no other 
known therapies that may effectively rescue the ischemic limb.
Mesenchymal stem cells (MSC) are pluripotent stem cells that can 
differentiate into osteoblasts, chondrocytes, adipocytes, neurons, skeletal 
muscle cells, endothelial cells and vascular smooth muscle cells 3,5-10. They are 
also known to secrete various cytokines that promote angiogenesis and 
vasculogenesis. Furthermore, MSCs are considered advantageous for clinical 
application of cell therapy since they do not induce immunological responses 
and therefore do not need main histocompatibility match for allogeneic 
transplantation 9,11. Therapeutic angiogenesis or vasculogenesis is a treatment 
targeted to induce new blood vessel formation for improved perfusion of 
ischemic tissues 12,13 and has a promising potential for the treatment of CLI.
Several studies reported that transplanted MSCs induced angiogenesis and 
improved blood flow to ischemic limbs in rat models of hind limb ischemia
7,14,15. However, due to the local hypoxia, oxidative stress and inflammation in 
3the target ischemic tissue, the survival of transplanted MSCs is poor and the 
therapeutic effects remain attenuated. Thus, it is critical to find techniques to 
enhance survival of transplanted MSCs in the target tissue.
Stromal-derived factor (SDF)-1, is also known as CXCL12, a potent 
chemoattractant of stem cells and progenitor cells. SDF-1 is mainly expressed 
by bone marrow stromal cells and endothelial cells and its production is 
increased under ischemic conditions. SDF-1 plays a significant role in the 
process involving stem/progenitor cell chemotaxis and organ-specific homing 
in ischemic tissue through interaction with its receptor CXC chemokine 
receptor 4 (CXCR4) on the surface of stem/progenitor cells. Administration of 
SDF-1 has shown to increase the number of circulating endothelial progenitor 
cells (EPCs) and to improve endothelial function 16,17. SDF-1 also improved
cardiomyocyte survival, neovascularization, and cardiac function after 
myocardial infarction 18-21.
Recent studies reported that oral sitagliptin, an inhibitor of dipeptidyl 
peptidase-4 (DPP-4) was able to increase circulating endothelial progenitor
cells possibly by up-regulation of SDF-1. DPP-4 is known to cleave various
bioactive molecules such as SDF-1 and glucagon-like peptide-1 (GLP-1) 16,22,23.
4Therefore, the purpose of this study is to investigate whether combined 
treatment of oral sitagliptin and local injection of MSCs may have synergistic 
effects on angiogenesis and blood perfusion recovery in a murine hind limb 
ischemia model by up-regulation of SDF-1.  
5II. MATERIALS AND METHODS
2.1. Reagents
Sitagliptin (Januvia®) was purchased from Merck. Anti-VEGF 
(1:1000), Anti-SDF-1 (1:1000), and Anti-CXCR4 (1:1000) antibodies were 
obtained from Abcam (Cambridge, MA, USA), and Anti-GAPDH was 
purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA).
2.2. Animals
All female C57BL/6 mice at 7-week-old (20-22g body weight) were 
purchased from Orient Bio (Sungnam, Korea). A total of 28 mice were devided 
into 4 groups; group 1 treated with oral saline and local injection of saline, 
group 2 treated with oral sitagliptin and local injection of saline, group 3 treated 
with oral saline and local injection of MSCs, and group 4 treated with oral 
sitagliptin and local injection of MSCs. Experiments were approved by the 
Institutional Animals Care and Use Committee of Yonsei University College of 
Medicine and performed in accordance with “Guide for the Care and Use of 
Laboratory Animals” published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996).
62.3. Cell Culture
Human mesenchymal stem cells (hMSCs) were obtained from Lonza 
Walkersville Inc. (Walkersville, MD, USA). The hMSCs were maintained under 
DMEM-low glucose (Gibco, Grand Island, NY, USA) with 10% fetal bovine 
serum (Gibco), 1% penicillin/streptomycin at 37℃ humidified atmosphere 
containing 5% CO2-95% air. DMEM was refreshed every one day until sub-
confluent. All experiments were performed using cells between passage 
numbers 5 to 7.
2.4. Mouse Hind limb Ischemia 
The mice were anesthetized by an intraperitoneal injection of 
0.05mg/kg (Zoletile Virbac, Carros Cedex, France) and xylazine 0.15ml/kg 
(Rompen, Bayer, Leverkusen, Germany). After the skin incision, the proximal 
and distal portions of the external femoral artery and all of the above saphenous 
artery was ligated. The femoral arterial and all side branches artery were 
dissected and excised 20.
2.5. Sitagliptin Administration and hMSC Transplantation
Sitagliptin (Januvia®) was obtained from Merck Sharp & Dohme Corp 
Korea. Sitagliptin 20 mg/kg body weight or 500 μl of saline per mouse was 
7administered daily after the onset of ischemia using oral gavage. Local injection 
of MSC (106 cells/200 μl) or saline 200 μl into the ischemic thigh muscle of 
four different sites was performed using with a 26 gauge needle under local 
anesthesia at 3 days after induction of the hind limb ischemia. Sitagliptin 
(20mg/kg BW), or saline was orally administered for 28day.
2.6. Measurement of Laser Doppler Blood Perfusion Imaging
A laser-Doppler image system (Moor LDI2, Moor Instruments, 
Axminster, UK) was used to measure blood flow perfusion before and at 7, 21, 
and 28 days after limb ischemia surgery. Before imaging, excess fur were 
removed from the limbs using depilatory cream, and mice were placed on a 
temperature controller at 37℃. Relative blood perfusion data were expressed as 
the ratio of the ischemic (left) to non-ischemic (right) limb blood flow.
2.7. Histological Assessment for Capillary Density
Ischemic limb gastrocnemius muscle were harvested 28 days after 
induction of ischemia, immersion-fixed with 4% buffered paraformaldehyde, 
and subsequently embedded in paraffin. Rabbit anti-mouse CD31 (dilution 
1:200; polyclonal; Abcam) was used to determine the capillary density on 2-
μm-thick paraffin-embedded sections using standard immunofluorescence. This 
measurement was determined in three randomly selected low-power (original 
8magnification x200) fields from each animal, and the average value was used as 
a single data for each animal.
2.8. Immunoblot analysis
For immunoblotting, homogenates and sonicator of limb muscle tissue 
were analyzed. Equal amounts of proteins were loaded and separated in 10%, 
12.5% and 15% SDS-polyacrylamide/bis-acrylamide gel electrophoresis and 
transferred to poly vinylidene difluoride membrane (Bio-Rad Laboratories, Inc. 
Hercules, CA, USA). The membrane was blocked for 1hr by 10% skim milk. 
Thereafter, the membrane was washed 3 times with TBS-tween 20 (TBS-T, 0.1% 
tween 20) for 7 min at room temperature. Membrane was incubated with 
primary antibodies for overnight at 4℃. Membrane was washed five times with 
TBS-T for 7 min, and incubated for 1hr at room temperature with horseradish 
peroxidase (HRP)-conjugated secondary antibodies. After extensive washing, 
the bands were evaluated.
2.9. Reverse transcription polymerase reaction (RT-PCR)
Total RNA from frozen muscle was isolated using the Qiazol-Reagent. 
cDNA synthesis was then performed using 1ug of RNA with the TaKaRa Ex 
Taq™ polymerase (Takara Bio, Otsu, Shiga, Japan). Levels of mRNA were 
analyzed by RT-PCR using the primers shown in Table 1. PCR products were 
9separated by electrophoresis in a 1.2% agarose-gel containing Gel-red (Biotium, 
Hayward, CA, USA).
10
Table 1. PCR primers used in this study
Gene Primer Size(bp) Temp.(℃)
VEGF 5'- GTA CCT CCA CCA TGC CAA GT -3' 340 58
5'- GCA TTC ACA TCT GCT GTG CT -3'
SDF-1 5' -GCT CTG CAT CAG TGA CGG TA -3' 306 58
5'- CTT TTC TGG GCA GCC TTT CT -3'
CXCR4 5'- TCC TGC CCA CCA TCT ACT TC -3' 342 58
5'- TTT CAG CCA GCA GTT TCC TT -3'
GAPDH 5'- ACT CCA CTC ACG GCA AAT TC-3' 370 58
5'- CCT TCC ACA ATG CCA AAG TT -3'
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2.10. Statistical Analysis
Statistical analysis was performed using IBM PASW Statistics 20.0 
software (IBM Corp, Armonk, NY, USA). All results are expressed as means ± 
standard deviation. Comparisons of continuous variables among the groups 
were performed using Student’s t test or ANOVA. A P value of <0.05 was 
considered statistically significant.
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III. RESULTS
1. Sitagliptin-hMSCs administration promoted reperfusion of blood flow in 
the ischemia limbs 
Representative images of laser Doppler perfusion scan before and 
immediately after induction of hind limb ischemia were shown in Figure 1A. 
Serial follow-up images of laser Doppler perfusion scan at 7, 14, 21, and 28 
days were presented in Figure 1B. At 28 day, group 4 with combined therapy of 
oral sitagliptin and local hMSCs showed the highest blood perfusion ratio (0.60 
± 0.1; P < 0.05 vs. other groups). The blood perfusion ratio in group 2 and 3 
was 0.48 ± 0.08 and 0.55 ± 0.09, respectively. These values were significantly 
higher than that of group 1 (0.44 ± 0.12, P < 0.05). However, the combined use 
of sitagaliptin-hMSCs further improved angiogenesis (perfusion ratio of). There 
was no significant difference in blood flow for sitagliptin administration and 
saline between days 7 and 28 (Figure 1C).
13
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Figure 1. Femoral artery blood flow by laser-Doppler perfusion imaging in 
combination of sitagliptin-hMSCs increases neovascularization in hind
limb ischemia. (A) Representative results of laser Doppler perfusion imaging
before and immediately after induction of hind limb ischemia (left, ischemic;
right non-ischemic hind limbs); (B) Representative results of laser Doppler 
perfusion imaging at 7, 14, 21 and 28days after hind limb ischemia surgery. In 
color-coded images, normal blood perfusion is displayed as red, whereas low or 
absent blood perfusion is displayed as blue; (C) Laser-Doppler ischemic/non-
ischemic limb blood perfusion ratios. (**P<0.01 for saline vs. sitagliptin + 
hMSCs; +p<0.05 for saline vs. sitagliptin + hMSCs; *p<0.01 for saline vs.
hMSCs, #p<0.05 for sitagliptin vs. sitagliptin + hMSCs)
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2. Sitagliptin-hMSCS improve angiogenesis in ischemic hind limb
Immunohistochemical staining of the shows CD31- and DAPI-positive 
cells (Figure 3A). The capillary density was significantly higher in group 3
(hMSCs) and 4 (sitagliptin-hMSCs) than in group 1 (saline) or 2 (sitagliptin)
(*p < 0.01 vs. saline group; ▲p < 0.01 vs. Sitagliptin; #p < 0.01 vs. MSC)
(Figure 3B). There was no significant difference in capillary density between 
group 3 and 4. However, there was a trend toward a higher capillary density in 
group 4.
18
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Figure 2. Effects of sitaglitin-hMSCs on angiogenesis in ischemic limbs. (A) 
Capillaries (red) were identified by CD31staining, a marker for endothelial cells. 
CD31 was also observed with confocal microscopy using primary anti-
PECAM1 antibody and Alexa-conjugated secondary antibody. (B)
Quantitatively expressed as a capillary number per muscle fiber on 28days after 
operation (n=3; for each experimental group, original magnification, x200).
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3. Sitaglipin-hMSCs increases VEGF expression in hind limb ischemia 
muscle
Representative Western blot data of VEGF protein expression are 
shown in Figure 3. There was increased VEGF expression in group 2 and group 
4 compared to group 1 or group 3 (Figure 3A). Similarly to protein expression, 
that total RNA expression of VEGF was higher in group 2 and 4 group 
compared to that in group 1 and 3 (Figure 3B)
21
Figure 3. Effects of sitagliptin-hMSCs on VEGF expression levels hind limb 
ischemia injury model. (A) Gastrocnemius muscle tissues were collected at 7
days after hind-limb ischemia injury. Muscle tissue lysates were separated by 
SDS-PAGE gel and analyzed by immunoblot analysis with antibodies against 
anti-VEGF and anti-GADPH antibody. (GADPH was loading control n=4). The 
protein expression of VEGF was slightly increased in group 2 (sitagliptin) and 
group 4 (sitagliptin-hMSCs) than in group 1 (saline) and group 3 (hMSCs). (B)
Total RNA was analyzed by Reverse transcription-polymerase chain reaction 
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(RT-PCR) using primers specific of VEGF and GAPDH gene in ischemic
muscle tissues (GAPDH was used as the internal control. n=4). The total RNA 
expressions of VEGF was slightly increased in group 2 (sitagliptin) and group 4 
(sitagliptin-hMSCs) than in other groups.
23
4. Sitaglin-hMSCs increases SDF-1 expression and secretion in hind limb 
ischemia
Western blot data show no significant difference in SDF-1 protein 
expression among the groups (Figure 4A). However, there was increased RNA 
expression of SDF-1 in group 3 and 4 compared to that of group 1 and 2. 
However, SDF-1 RNA expression was similar between group 3 and 4 (Figure 
4B). Interestingly, western blot analysis using serum showed significantly 
increased protein level of SDF-1 in group 4 compared with other groups (Figure 
4C).
24
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Figure 4. Effects of sitagliptin-hMSCs on SDF-1 expression levels in hind
limb ischemia model. (A) Representative Western blot of SDF-1 protein level 
in the gastrocnemius muscle tissues at 7 days after limb ischemic injury (n=2).
The protein expression of SDF-1 was lower in group 1 (saline) than in other 
groups. (GADPH was used as the internal control. n=2). (B) RNA was analyzed 
by Reverse transcription-polymerase chain reaction (RT-PCR) using primers 
specific of SDF and GAPDH gene in ischemic muscle tissues. (GAPDH was 
used as the internal control. n=4). (C) The protein expression of SDF-1 was
significant higher in sitagliptin-hMSCs combination therapy group than in other 
groups (n = 4) *P < 0.01
26
5. Sitagliptin increases CXCR4 expression in hind limb ischemia muscle
There was increased expression level of CXCR4 in group 2 and 4 than 
in group 1 and 3 (Figure 5A). RNA expression level of CXCR4 similarly 
increased in group 2, 3, and 4 was higher than in group 1 (Figure 5B).
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Figure 5. Effects of sitagliptin on CXCR4 expression levels in hind limb 
ischemia. (A) Gastrocnemius muscle tissues were collected 7 days after hind-
limb ischemia injury. Muscle tissue lysates were separated by SDS-PAGE gel 
and analyzed by immunoblot analysis with antibodies against anti-CXCR4 and 
anti-GADPH antibody. (GADPH was used as the internal control. n=4). The 
protein expression of CXCR4 was increased in group 2 (sitagliptin) and group 4 
(sitagliptin-hMSCs) than in group 1 (saline) and group 3 (hMSCs). (B) RNA 
was analyzed by Reverse transcription-polymerase chain reaction (RT-PCR)
using primers specific of CXCR4 and GAPDH gene in ischemic muscle tissues
28
(GAPDH was used as the internal control. n=4). The RNA expression of 
CXCR4 was significantly higher in group 2 (sitagliptin) and group 4 
(sitagliptin-hMSCs). 
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IV. DISCUSSION
The major finding of study was that combined treatment of oral 
sitagliptin and local injection of MSCs achieved more effective angiogenic 
response in a mouse hind limb ischemia model than oral sitagliptin 
administration or local MSC transplantation alone. The combination therapy 
was associated with increased expression of VEGF, SDF-1 and CXCR4.
Mesenchymal stem cell (MSC) is a multipotent stem cell that can 
differentiate into a variety of cell types. Various studies demonstrated 
therapeutic angiogenic effects of MSCs in animal models of peripheral arterial 
disease and myocardial infarction 5,15,24,25. However, the mechanisms 
underlying the effects of MDSCs remain still unclear. Stem cell can either 
directly increase angiogenesis by transforming into endothelial cells and 
proliferation or indirectly by secreting various angiogenic growth factors and 
anti-apoptotic factors. But, there are several shortcomings in using MSCs for 
cell therapy of ischemic diseases. The repair capability of MSCs declines with 
age and diseases 24,26-29. Also, the viability of MSCs in ischemic condition is 
low. Thus, it is crucial to improve MSC survival against the hypoxia and 
hypertrophic microenvironment 30-33. There have been various studies focused 
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on treatment strategies to improve survival of transplanted MSCs in the target 
organs 34-37.
Sitagliptin, an anti-diabetic drug, is an inhibitor of DPP-4. DPP-4 
cleaves various substrates, including GLP-1 and SDF-1. Increased activity of 
DPP-4 in blood has shown to decrease the circulating concentration of SDF-1a
38. SDF-1 has been found to be involved in mobilization and recruitment of 
endothelial progenitor cells after arterial injury in mice 39,40. Up-regulation of 
SDF-1, CXCR4, and VEGF in the damaged tissue has been shown to play a 
critical role in recruiting stem cells to ischemic tissue 19,41,42. Another 
experiment study demonstrated that SDF-1 pretreatment can improve MSC 
migration, cytokine production, and cell survival after exposure to hypoxia 43-45. 
In our study, expressions of SDF-1, CXCR4, VEGF were increased in all 
animals treated with oral sitagliptin, local transplantation of MSCs, or the 
combined treatment compared with control group. However, we could not 
prove whether the expression of these angiogenic factors was statistically 
higher in the combination group than in the monotherapy of sitagliptin or MSCs 
due to small numbers of study animals.  However, there was signicantly 
improved angiogenic response measured in blood flow ratio by laser Doppler 
perfusion scan and capillary density for the combination therapy group than 
monotherapy of oral sitagliptin or local transplantation of MSCs. Therefore, we 
31
assume that additive effects of sitagliptin and MSCs may be achieved by up-
regulation of SDF-1/CXCR4 axis and activation of MSCs. 
A major limitation of the present study was that insufficient data to 
prove working mechanisms of the combined therapy of sitagliptin and MSCs 
for improved angiogenic response Furthermore, we could not also demonstrate 
prolonged survival or increased activity of MSCs in ischemic limbs.
32
V. CONCLUSION
The combination therapy of oral sitagliptin and local transplantation of 
MSCs was more effective in enhancing angiogenic responses to limb ischemia 
than oral sitagliptin or local transplantation of MSCs alone possibly due to up-
regulation of SDF-1. Our results suggest that this combined treatment may have 
a potential as a new therapeutic strategy to treat severe peripheral arterial
disease.
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ABSTRACT (in Korean)
하지허혈 모델에서 골수유래 중간엽줄기세포의 혈관재생효과에
미치는 DPP4 저해제의 영향에 관한 연구
<지도교수 고 영 국>
연세대학교 대학원 노화과학협동과정
임 희 정
Background: 중간 엽 줄기 세포는 중증 하지 허혈에 대한 치료
가능성을 갖는 것으로 알려져 있다. 그러나 허혈 조직에 중간 엽
줄기 세포 주입이 낮은 생존율로 인해 줄기세포 치료의 혈관 신생을
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약화 시키는 것이 중요한 요인이다. 따라서 우리는 sitagliptin, DPP-4 
억제제가 SDF-1 의 발현에 의해 하지 허혈 쥐 모델에서 중간 엽
줄기세포의 혈관 신생 반응을 향상 시킬 수 있는지 알아보고자 한다. 
Methods and Results: 하지 허혈 유도 후 네 군으로 분류하였다. 각각
Group 1 saline 경구 투여, group 2는 sitagliptin 경구 투여, group 3 saline 
경구 투여 및 중간 엽 줄기 세포의 주입, group4 sitagliptin 경구 투여
및 중간 엽 줄기세포 주입으로 나누어 진행하였다. 레이져 도플러
관류 영상을 통해 혈관 신생을 측정하였으며, 근육 모세관 밀도와
SDF-1, CXCR4, VEGF 같은 혈관 신생 인자의 mRNA와 단백질 발현을
알아보았다. 하지 허혈 모델에서 Sitagliptin 과 중간 엽 줄기 세포
동시 투여 군이 sitagliptin 단독 투여 군 또는 hMSCs 단독 주입 군에
비해 혈관 신생 효과가 있는 것을 확인하였다. 또한 Sitagliptin 과
중간 엽 줄기세포 동시 투여 치료법은 하지 허혈 모델에서 VEGF, 
SDF-1, CXCR4의 발현이 증가하는 것을 입증하였다. 
Conclusions: 하지 허혈에서 Sitagliptin 과 중간 엽 줄기 세포의 동시
투여는 sitagliptin 단독 투여와 중간 엽 줄기 세포 단독 주입
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치료법보다 혈관 신생 반응을 촉진한다. 이는 SDF-1 과발현에 의해
혈관 신생을 촉진 되는 것을 확인하였다.
핵심되는 말: 하지 허혈, sitagliptin, SDF-1/CXCR4, 혈관신생반응
